BibTex RIS Cite

Year 2007, Volume: 20 Issue: 1, 1 - 5, 25.06.2015

Cenk Aral Sinan Çağlayan Gökhan Özışık Şirin Massoumilary Özgür Sönmez Mustafa Akkiprik Hüseyin Baloğlu Metin Özata Ayşe Özer

Abstract

References

  • Liska J, Altanerova V, Galbavy S, Stvrtina S, Brtko J. Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul 2005;39:73-83.
  • Farid NR, Shi Y, Zou MJ. Molecular basis of thyroid cancer. Endocr Rev 1994;15:202–232.
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614.
  • Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-1089.
  • Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-690.
  • Weston A, Godbold JH. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 1997;105:919-926.
  • Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377385.
  • Weston A, Wolff MS. True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 1998;102:153-154.
  • Papadakis EN, Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000;3:389-392.
  • Boltze C, Roessner A, Landt O, Szibor E, Peters B, Schneider-stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002;21:1151–1154.
  • Granja F, Morari J, Morari EC, Correa LAC, Assumpcao LVM , Ward LS. Proline homozygosity in codon 57 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 2004;210:151-157.
  • John SWM, Weitzner G, Rozen R, Scriver CR. A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1991;19:408.
  • Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual.6th edition, Springer, New York, 2002.
  • Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961–963.
  • Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357–365.
  • Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47–54.
  • Lee JM, Shun CT, Wu MT, et al. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 2006;594:181–188.
  • Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;12:1426-1429.

TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ

Year 2007, Volume: 20 Issue: 1, 1 - 5, 25.06.2015

Cenk Aral Sinan Çağlayan Gökhan Özışık Şirin Massoumilary Özgür Sönmez Mustafa Akkiprik Hüseyin Baloğlu Metin Özata Ayşe Özer

Abstract

Amaç: Tiroid kanseri en sık görülen endokrin malignitedir. Hastalığa yol açan moleküler mekanizmalar çeşitlilik göstermektedir. p53 geninin polimorfik varyantları ile çeşitli insan kanserleri arasındaki ilişki gösterilmiştir. Bunlar arasında kodon 72 en sık çalışılan varyanttır ancak tiroid kanseri ile ilgili sadece 2 çalışma mevcuttur. Bu çalışmada Türk hastalarda p53 kodon 72 polimorfizmi ile tiroid kanseri arasındaki ilişkinin araştırılması amaçlanmıştır. Materyal ve Metot: 58 tiroid kanser hastasının ve 115 sağlıklı bireyin genotip analizi PCR-RFLP yöntemi ile yapılmıştır. Sonuçlar: Polimorfik prolin allel sıklığı hastalarda kontrollerden daha yüksektir. Pro/Pro genotipi tirod kanser gelişimi için bir risk faktörü olarak bulunmuştur. Arg/pro genotip sıklığı açısından hasta ve kontrol grupları arasında farklılık bulunmamıştır. Foliküler adenom ve papiller karsinom hastaları veya papiller karsinom hastalarının TNM evrelendirmeleri açısından kodon 72 genotipleri açısından bir fark bulunmamıştır. Tartışma: Tiroid kanser gelişimine neden olan moleküler mekanizmaların aydınlatılabilmesi için farklı populasyonlarda kodon 72 polimorfizmi ile birlikte diğer genetik faktörlerin de çalışılmasına gereksinim vardır.

Anahtar kelimeler: Tiroid kanseri, p53 kodon 72, polimorfizm

Keywords

Tiroid kanseri p53 kodon 72 polimorfizm

References

  • Liska J, Altanerova V, Galbavy S, Stvrtina S, Brtko J. Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul 2005;39:73-83.
  • Farid NR, Shi Y, Zou MJ. Molecular basis of thyroid cancer. Endocr Rev 1994;15:202–232.
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614.
  • Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-1089.
  • Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-690.
  • Weston A, Godbold JH. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 1997;105:919-926.
  • Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377385.
  • Weston A, Wolff MS. True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 1998;102:153-154.
  • Papadakis EN, Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000;3:389-392.
  • Boltze C, Roessner A, Landt O, Szibor E, Peters B, Schneider-stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002;21:1151–1154.
  • Granja F, Morari J, Morari EC, Correa LAC, Assumpcao LVM , Ward LS. Proline homozygosity in codon 57 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 2004;210:151-157.
  • John SWM, Weitzner G, Rozen R, Scriver CR. A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1991;19:408.
  • Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual.6th edition, Springer, New York, 2002.
  • Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961–963.
  • Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357–365.
  • Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47–54.
  • Lee JM, Shun CT, Wu MT, et al. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 2006;594:181–188.
  • Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;12:1426-1429.
There are 18 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Cenk Aral This is me

Sinan Çağlayan This is me

Gökhan Özışık This is me

Şirin Massoumilary This is me

Özgür Sönmez This is me

Mustafa Akkiprik This is me

Hüseyin Baloğlu This is me

Metin Özata This is me

Ayşe Özer

Publication Date June 25, 2015
Published in Issue Year 2007 Volume: 20 Issue: 1

Cite

APA Aral, C., Çağlayan, S., Özışık, G., Massoumilary, Ş., et al. (2015). TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ. Marmara Medical Journal, 20(1), 1-5.
AMA Aral C, Çağlayan S, Özışık G, Massoumilary Ş, Sönmez Ö, Akkiprik M, Baloğlu H, Özata M, Özer A. TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ. Marmara Med J. August 2015;20(1):1-5.
Chicago Aral, Cenk, Sinan Çağlayan, Gökhan Özışık, Şirin Massoumilary, Özgür Sönmez, Mustafa Akkiprik, Hüseyin Baloğlu, Metin Özata, and Ayşe Özer. “TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ”. Marmara Medical Journal 20, no. 1 (August 2015): 1-5.
EndNote Aral C, Çağlayan S, Özışık G, Massoumilary Ş, Sönmez Ö, Akkiprik M, Baloğlu H, Özata M, Özer A (August 1, 2015) TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ. Marmara Medical Journal 20 1 1–5.
IEEE C. Aral, S. Çağlayan, G. Özışık, Ş. Massoumilary, Ö. Sönmez, M. Akkiprik, H. Baloğlu, M. Özata, and A. Özer, “TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ”, Marmara Med J, vol. 20, no. 1, pp. 1–5, 2015.
ISNAD Aral, Cenk et al. “TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ”. Marmara Medical Journal 20/1 (August 2015), 1-5.
JAMA Aral C, Çağlayan S, Özışık G, Massoumilary Ş, Sönmez Ö, Akkiprik M, Baloğlu H, Özata M, Özer A. TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ. Marmara Med J. 2015;20:1–5.
MLA Aral, Cenk et al. “TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ”. Marmara Medical Journal, vol. 20, no. 1, 2015, pp. 1-5.
Vancouver Aral C, Çağlayan S, Özışık G, Massoumilary Ş, Sönmez Ö, Akkiprik M, Baloğlu H, Özata M, Özer A. TİROİD KANSERLİ TÜRK HASTALARDA P53 KODON 72 POLİMORFİZMİ. Marmara Med J. 2015;20(1):1-5.